Beyond Efficacy: Ensuring Safety in Peptide Therapeutics through Immunogenicity Assessment
Journal of Peptide Science · 2025-06 · 31 (6)
DOI: 10.1002/psc.70016 ↗At a glance
Übersichtsarbeit in Journal of Peptide Science, published online on 2025-04-21. Written by Koulla Achilleos and 3 co-authors. Institution: Department of Health Sciences, School of Life & Health Sciences, University of Nicosia, Nicosia, Cyprus. Major MEDLINE topics: Peptides. Cited 51 times so far (Crossref); 61 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Research and Innovation Foundation of Cyprus.
Abstract (original language)
Peptides are gaining remarkable popularity in clinical diagnosis and treatment due to their high selectivity and minimal side effects. Over 11% of all new pharmaceutical chemical entities authorised by the FDA between 2016 and 2024 were synthetically manufactured peptides. A critical factor that can potentially limit the efficacy and safety of peptide‐based therapeutics or biologics is immunogenicity, defined as an unintended or adverse immune response to a protein or peptide therapy. This response may be triggered by the peptide itself or by impurities in the production or formulation steps, leading to the production of antidrug antibodies (ADAs). To address this, current regulatory guidelines require the assessment of risks in market authorization applications, which include identifying drug impurity levels and immunogenicity. The development and critical evaluation of appropriate immunogenicity assays is therefore highly warranted. Such assays must consider the fine complexities of the immune response, as well as its variation within the human population. Moreover, immunogenicity testing is expected to remain a priority as the shift toward greener chemistries in peptide synthesis may require reassessment of novel impurities in peptide formulations.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Health Sciences, School of Life & Health Sciences, University of Nicosia, Nicosia, Cyprus.
- Bioactive Molecules Research Center, School of Life & Health Sciences, University of Nicosia, Nicosia, Cyprus.
- Department of Life Sciences, School of Life & Health Sciences, University of Nicosia, Nicosia, Cyprus.
ORCID profiles: Yiannis Sarigiannis
Funding
- Research and Innovation Foundation of Cyprus
Cite
APA
Achilleos, K., Petrou, C., Nicolaidou, V., & Sarigiannis, Y. (2025). Beyond Efficacy: Ensuring Safety in Peptide Therapeutics through Immunogenicity Assessment. Journal of Peptide Science, 31(6). https://doi.org/10.1002/psc.70016
Vancouver
Achilleos K, Petrou C, Nicolaidou V, Sarigiannis Y. Beyond Efficacy: Ensuring Safety in Peptide Therapeutics through Immunogenicity Assessment. Journal of Peptide Science. 2025;31(6). doi:10.1002/psc.70016
BibTeX
@article{Achilleos2025,
author = {Achilleos, Koulla and Petrou, Christos and Nicolaidou, Vicky and Sarigiannis, Yiannis},
title = {Beyond Efficacy: Ensuring Safety in Peptide Therapeutics through Immunogenicity Assessment},
journal = {Journal of Peptide Science},
year = {2025},
volume = {31},
number = {6},
doi = {10.1002/psc.70016}
}
EUVIMED